[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 4,406
Invited Commentary
Health Informatics
August 3, 2018

Machine Learning for Prediction in Electronic Health Data

Author Affiliations
  • 1Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts
JAMA Network Open. 2018;1(4):e181404. doi:10.1001/jamanetworkopen.2018.1404

Machine learning for prediction in electronic health data has been deployed for many clinical questions during the last decade. Machine learning methods may excel at finding new features or nonlinear relationships in the data, as well as handling settings with more predictor variables than observations. However, the usefulness of both these data and machine learning has varied. Electronic health data often have quality issues (eg, missingness, misclassification, measurement error), and machine learning may perform similarly to standard techniques for some research questions. Ensembles (running multiple algorithms and either selecting the single best algorithm or creating a weighted average) can help mitigate the latter concern. Using several machine learning tools, Wong et al1 predicted delirium risk for newly hospitalized patients with high-dimensional electronic health record data at a large academic health institution. They compared these approaches with a questionnaire-based scoring system and found improved performance for machine learning with respect to several metrics calculated in a single holdout sample. Their article is a step toward updating delirium risk prediction. It also provides an opportunity to discuss 2 key issues in the current state of machine learning for prediction in electronic health data: evaluation and generalizability.

The machine learning researchers who develop novel algorithms for prediction and the clinical teams interested in implementing them are frequently and unfortunately 2 nonintersecting groups. Thus, these algorithms may originally be built and evaluated in the machine learning literature based on metrics that are less clinically useful than other choices. Computer scientists and statisticians may optimize to achieve the best area under the receiver operating characteristic curve (AUC), but what a clinical team might need is high sensitivity or positive predictive value. Worse yet, algorithms can have misleading performance when evaluated only along 1 or 2 dimensions. For example, high AUC, accuracy, and positive predictive values can be accompanied by near-zero levels of sensitivity and specificity. It can also be essential to calculate metrics like the percentage of true cases in the top risk percentile.2 This is especially important when a goal of the tool is to target high-risk patients for interventions. Wong and colleagues1 helpfully compute AUC, positive predictive values, sensitivity, and specificity. However, one accepted standard for evaluation that should be adopted in future clinical machine learning applications is K-fold cross-validation (eg, with K = 10) rather than the single holdout validation sample in their article. K-fold cross-validation involves K successive mutually exclusive validation sets where the algorithm fitting is iteratively performed on the nonvalidation data (ie, training set). At the end, each observation in the full data has a predicted value that was obtained from when it was part of a validation set. Typically, metrics calculated based on these K-fold cross-validated predicted values will more effectively assess overfitting and have lower variance.3

Of course, assessing the generalizability of a prediction algorithm goes well beyond using cross-validated metrics to evaluate overfitting. Wong et al1 carefully discussed a number of limitations in their work, including the lack of external validation in other health systems. As in similar studies, the step from good performance in the study to a generalizable algorithm is vast and sometimes may not be feasible. Patients receiving treatment in varied care settings or geographic regions simply may require tailored tools. Recognizing the need for unique tools in different populations is not inherently negative, but one of many considerations not magically solved by using machine learning. Even those algorithms that prove to be generalizable may quickly become outdated as treatment patterns or physician incentives to code health conditions change.4 Increased social tolerance for certain conditions, such as mental health and substance use disorders, may also necessitate updating tools. How often algorithms should be reevaluated will depend on many of these factors.

When implementing machine learning for prediction in electronic health data, it is critical to remember that these data are not collected to answer specific research questions, which is a central difficulty in relying on them for these purposes. Machine learning might or might not provide benefits and the data might not be robust enough to be useful to clinical teams. Prediction algorithms that combine the best clinical expertise with rigorous machine learning tools are the most promising for continued work.5,6 Wong et al1 brought this to their study by using an expert clinical panel to select the 796 predictor variables available to their machine learning algorithms, while still allowing for automated variable selection. As Wong and colleagues1 also demonstrated, it is imperative to include a comparison to standard practice. Their top-performing algorithm improved nontrivially over the questionnaire-based scoring system, although some metrics were still low (59.7% sensitivity and 23.1% positive predictive value). Whether these levels are high enough to support use deserves further discussion. In general, algorithms can be designed with a priori thresholds for both improvement over current practice and the minimum level needed along each metric to warrant investing in establishing a new prediction system.

There is reason to be optimistic about the ability of machine learning to transform prediction in an array of medical fields. Machine learning also has demonstrated promise in clinical domains when the goal is to discover clusters in the data, such as imaging analysis for therapeutic selection.7 Here, the new features can be validated with expert evaluation from radiologists or neurologists, which differs from the prediction setting where observed labels exist in the data. Causal inference methods that incorporate machine learning8 are a burgeoning area, including techniques for treatment effect heterogeneity.9 Understanding heterogeneous treatment effects will likely be one path in the journey toward precision medicine. That said, we are in a discovery phase, and the pervasiveness of electronic health big data across many clinical areas does not ultimately mean machine learning will be equally valuable in each.

Back to top
Article Information

Published: August 3, 2018. doi:10.1001/jamanetworkopen.2018.1404

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2018 Rose S. JAMA Network Open.

Corresponding Author: Sherri Rose, PhD, Department of Health Care Policy, Harvard Medical School, 180 Longwood Ave, Boston, MA 02115 (rose@hcp.med.harvard.edu).

Conflict of Interest Disclosures: Dr Rose reported grants from the National Institutes of Health (NIH) during the conduct of the study.

Funding/Support: Research reported in this publication was supported by the NIH through an NIH Director’s New Innovator Award DP2-MD012722.

Role of the Funder/Sponsor: The NIH had no role in the preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH.

References
1.
Wong  A, Young  AT, Liang  AS, Gonzales  R, Douglas  VC, Hadley  D.  Development and validation of an electronic health record–based machine learning model to estimate delirium risk in newly hospitalized patients without known cognitive impairment.  JAMA Netw Open. 2018;1(4):e181018. doi:10.1001/jamanetworkopen.2018.1018Google Scholar
2.
Steyerberg  EW, Vickers  AJ, Cook  NR,  et al.  Assessing the performance of prediction models: a framework for traditional and novel measures.  Epidemiology. 2010;21(1):128-138. doi:10.1097/EDE.0b013e3181c30fb2PubMedGoogle ScholarCrossref
3.
Kohavi  R. A study of cross-validation and bootstrap for accuracy estimation and model selection. Proc Int Joint Conf Artif Intell. 1995;14(2):1137–1145.
4.
Bergquist  S, Brooks  G, Keating  N, Landrum  MB, Rose  S.  Classifying lung cancer severity with ensemble machine learning in health care claims data. http://proceedings.mlr.press/v68/bergquist17a.html.  Proc Mach Learn Res. 2017;68:25-38.Google Scholar
5.
Verghese  A, Shah  NH, Harrington  RA.  What this computer needs is a physician: humanism and artificial intelligence.  JAMA. 2018;319(1):19-20. doi:10.1001/jama.2017.19198PubMedGoogle ScholarCrossref
6.
Beam  AL, Kohane  IS.  Big data and machine learning in health care.  JAMA. 2018;319(13):1317-1318. doi:10.1001/jama.2017.18391PubMedGoogle ScholarCrossref
7.
Sweeney  EM, Shinohara  RT, Dewey  BE,  et al.  Relating multi-sequence longitudinal intensity profiles and clinical covariates in incident multiple sclerosis lesions.  Neuroimage Clin. 2015;10:1-17. doi:10.1016/j.nicl.2015.10.013PubMedGoogle ScholarCrossref
8.
van der Laan  M, Rose  S.  Targeted Learning: Causal Inference for Observational and Experimental Data. New York, NY: Springer; 2011. doi:10.1007/978-1-4419-9782-1
9.
Athey  S, Imbens  G.  Recursive partitioning for heterogeneous causal effects.  Proc Natl Acad Sci U S A. 2016;113(27):7353-7360. doi:10.1073/pnas.1510489113PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×